Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 AlteredExpression group BEFREE A minimum set of markers was selected (levels of HMGA2 mRNA and miR-375, - 221, and -146b in combination with the mitochondrial-to-nuclear DNA ratio) and yielded highly accurate discrimination (sensitivity = 0.97; positive predictive value = 0.98) between goiters with benign tumors and malignant tumors and accurate typing of papillary, medullary, and Hürthle cell carcinomas. 31660895 2019
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 Biomarker group CTD_human SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome. 18413806 2008
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 AlteredExpression group BEFREE PAX3, TGFB2 and HMGA2 were expressed predominantly in borderline/malignant PTs, but showed some expression in benign tumours; they may be important in the transition from the benign to borderline/malignant phenotype. 18937276 2008
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 GeneticVariation group BEFREE This analysis clearly demonstrates that as a rule, germ line mutations of HMGA2 are not the cause for benign tumors, e.g. uterine leiomyomas, or human malignant solid tumors. 17094442 2006
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 Biomarker group BEFREE The high-mobility group A2 (HMGA2) gene has a critical role in benign tumors where it is frequently rearranged, and in malignant tumors, where it is overexpressed in the absence of structural modification of the HMGA2 locus. 16322327 2005
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 Biomarker group BEFREE The lipoma preferred partner (LPP) gene is the most frequent translocation partner of HMGA2 in a subgroup of lipomas, which are benign tumors of adipose tissue. 15755872 2005
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 GeneticVariation group BEFREE Chromosomal rearrangements of the HMGA2 locus belong to the most common aberrations in human benign tumors. 15882911 2005
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 GeneticVariation group BEFREE Deregulation of the HMGA2 gene is a common molecular alteration implicated in the development of a variety of benign tumors, such as lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas. 14612541 2003
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 Biomarker group BEFREE This finding suggests a role for the HMGI-C gene also in the pathogenesis of this uncommon benign tumor type, in addition to its well-established role in the pathogenesis of common benign tumors such as lipomas, uterine leiomyomas, pulmonary chondroid hamartomas, and endometrial polyps. 12021922 2002
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 GeneticVariation group BEFREE Fusion of the high-mobility group protein gene HMGIC to other genes due to chromosomal rearrangements occurs in a variety of human benign tumors. 11170289 2001
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 GeneticVariation group BEFREE Defects in the HMGI-C gene have been found in a variety of benign tumors, such as uterine leiomyomas, endometrial polyps, lipomas, and pulmonary chondroid hamartomas. 10998430 2000
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 AlteredExpression group BEFREE The general prevalence of HMGI-C and HMGI(Y) protein expression and its correlation with chromosomal alterations in these benign tumors are unknown. 10744071 2000
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 Biomarker group BEFREE The results strongly suggest that pleomorphic adenomas are the only exception to the rule that entities of benign tumors with HMGIC rearrangements also have subtypes with HMGIY rearrangements. 10347561 1999
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 GeneticVariation group BEFREE Rearrangements of the HMGI-C gene have frequently been detected in human benign tumors of mesenchymal origin, including lipomas. 10519386 1999
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.400 Biomarker group BEFREE Recently, the high mobility group protein gene, HMGIC, was identified as a common genetic denominator in benign tumors with chromosome 12q13-15 aberrations, such as lipomas, uterine leiomyomas, pleomorphic adenoma of the salivary glands, hamartomas of breast and lung, angiomyxomas, and endometrial polyps. 9169041 1997
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 PosttranslationalModification group BEFREE Our meta-analysis included eight eligible studies, with 428 ovarian cancers and 278 normal tissue samples and benign neoplasms. p16 promoter methylation was identified in 5.4 to 43.2% (median 27.86%) of ovarian cancers and 0 to 37.5% (median 15.8%) of normal tissue and benign neoplasms indicating that no significant association exists between p16 promoter methylation and epithelial ovarian cancer. 28000027 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 Biomarker group BEFREE p14 absent expression was associated with malignant tumors (60 % positive) (p = 0.000), while 93 % and 94 % of benign and borderline tumors, respectively, were positive. p16 was positive in 94.6 % of carcinomas, 75 % of borderline and 45.7 % of benign tumors (p = 0.000). p53 negative staining was associated with benign tumors (2.9 % positive) (p = 0.016) but no difference was observed between borderline (16.7 %) and malignant tumors (29.7 %) (p = 0.560). 27770808 2016
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 GeneticVariation group BEFREE The presence of BRAF V600E and mitogen-activated protein kinase activation in a largely benign tumor supports the necessity for secondary events (e.g., p16 loss) in BRAF-driven oncogenesis. 22727996 2012
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 Biomarker group BEFREE Using a cutoff threshold based on receiver-operating characteristic analysis, 21 patients with ovarian cancer and three patients with benign tumors were considered positive for CDKN2A methylation while all patients with healthy ovaries were considered negative. 21728901 2011
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 Biomarker group CTD_human Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. 19223589 2009
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 GeneticVariation group BEFREE No p14(ARF), p15(INK4B) and p16(INK4A) deletions or hypermethylation were observed in this benign tumor. 17203593 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 AlteredExpression group BEFREE We propose that LMP1 acts at the early stages in carcinogenesis to promote the development of benign tumours and that early reduction of INK4a locus expression allows these lesions to expand in size. 12807717 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 GeneticVariation group BEFREE Our results demonstrate that alterations of the INK4a-ARF locus are frequent and important events not only in the carcinogenesis of malignant, but also in benign tumors. 12924439 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 Biomarker group CTD_human Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. 11544531 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.380 Biomarker group BEFREE None of the benign tumors had CDKN2A/p16 deletions, whereas three of six MPNSTs appeared to have homozygous CDKN2A/p16 deletions. 10595918 1999